Roche Wins FDA Approval for Enspryng in Thyroid Eye Disease

Roche has received approval from the US Food and Drug Administration (FDA) for Enspryng (satralizumab) to treat adults with thyroid eye disease (TED). The approval introduces the first and only at-home subcutaneous treatment option for the condition, giving patients more flexibility in how they receive treatment.

Enspryng can be injected under the skin by patients themselves or by a caregiver after receiving training from a healthcare professional. During the maintenance phase, treatment can be administered every four weeks, potentially reducing the need for regular visits to healthcare facilities for infusion-based treatment.

The FDA decision is based on results from the Phase 3 SatraGO-1 and SatraGO-2 clinical trials, which evaluated Enspryng in adults with thyroid eye disease. The studies included 258 patients across 19 countries and assessed the drug’s effectiveness, safety and ability to provide lasting benefits.

In the SatraGO-2 study, 52.9% of patients with active thyroid eye disease who received Enspryng experienced a meaningful reduction in eye bulging, known medically as proptosis. This compared with 23.4% of patients receiving a placebo.

The study also found improvements in double vision, or diplopia. Around 60.7% of patients treated with Enspryng experienced a reduction in double vision, compared with 25.8% in the placebo group.

However, the results were not consistent across both trials. SatraGO-1 did not meet its predefined primary efficacy endpoint at Week 24, while SatraGO-2 demonstrated significant improvements in eye bulging and double vision. Roche reported that the safety findings across the studies were consistent with the drug’s established safety profile, with no new safety concerns identified.

“Today’s FDA approval of Enspryng provides an important new option for people with thyroid eye disease, who have long faced limited treatment choices,” said Levi Garraway, Roche’s chief medical officer and head of global product development.

César A. Briceño, an associate professor of ophthalmology at the University of Pennsylvania and a clinical trial investigator, said a targeted treatment given under the skin could offer greater flexibility for patients and doctors while reducing the practical challenges associated with infusion-based therapies.

Thyroid eye disease, also known as Graves’ ophthalmopathy, is an autoimmune condition that causes inflammation around the eyes. It can lead to eye redness, swelling, pain, bulging eyes and double vision. In severe cases, the disease can threaten sight and affect a person’s appearance and quality of life.

The condition is often associated with an overactive thyroid, although it can also occur in people with an underactive thyroid or normal thyroid function. Existing treatments can help manage the disease, but there remains a need for effective options that are easier to administer and suitable for long-term care.

Enspryng is a monoclonal antibody developed by Chugai Pharmaceutical, a member of the Roche Group. It targets the interleukin-6 receptor (IL-6R), blocking a signalling pathway involved in inflammation. The medicine uses antibody recycling technology designed to support sustained activity in the body.

The approval marks the second US indication for Enspryng, which was approved in 2020 to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease affecting the central nervous system.

Roche is also studying Enspryng in other neurological and autoimmune conditions, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The FDA granted priority review to the company’s application for MOGAD in September 2026, with a decision expected in January 2027.

The new approval expands treatment options for adults with thyroid eye disease and highlights the growing role of targeted therapies in autoimmune conditions. By offering an at-home injection option, Roche aims to make treatment more convenient for patients who need ongoing care.